Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples.
OBJECTIVE
We aimed to investigate the prevalence of erectile dysfunction (ED) and the usage of phosphodiesterase type 5 (PDE5) inhibitors for ED treatment in infertile couples.


METHODS
A total of 260 male partners in couples reporting infertility lasting at least 1 year were included in this study. In addition to an evaluation of infertility, all participants completed the International Index of Erectile Function (IIEF)-5 questionnaire to evaluate their sexual function. The participants were asked about their use of PDE5 inhibitors while trying to conceive during their partner's ovulatory period and about their concerns regarding the risks of PDE5 inhibitor use to any eventual pregnancy and/or the fetus.


RESULTS
Based on the IIEF-5 questionnaire, 41.5% of the participants (108/260) were classified as having mild ED (an IIEF-5 score of 17-21), while 10.4% of the participants (27/260) had greater than mild ED (an IIEF-5 score of 16 or less). The majority (74.2%, 193/260) of male partners of infertile couples had a negative perception of the safety of using a PDE5 inhibitor while trying to conceive. Only 11.1% of men (15/135) with ED in infertile couples had used a PDE5 inhibitor when attempting conception.


CONCLUSIONS
ED was found to be common in the male partners of infertile couples, but the use of PDE5 inhibitors among these men was found to be very low. The majority of male partners were concerned about the risks of using PDE5 inhibitors when attempting to conceive. Appropriate counseling about this topic and treatment when necessary would likely be beneficial to infertile couples in which the male partner has ED.
Department of Urology, Fertility Center of CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Seung-Hun
SH
Song
Department of Urology, Fertility Center of CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Dong Suk
DS
Kim
Department of Genetics, CHA University, Seoul, Korea.
Sung Han
SH
Shim
Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Canada.; Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Canada.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada.
Jung Jin
JJ
Lim
Department of Urology, Fertility Center of CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Seung Choul
SC
Yang
Erectile dysfunction; Infertility; Phosphodiesterase 5 inhibitor